AffimedAFMD
Market Cap: $57.3M
About: Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Employees: 78
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
562% more call options, than puts
Call options by funds: $3.05M | Put options by funds: $461K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
8% more capital invested
Capital invested by funds: $15M [Q1] → $16.3M (+$1.25M) [Q2]
0.66% more ownership
Funds ownership: 19.0% [Q1] → 19.66% (+0.66%) [Q2]
7% less funds holding
Funds holding: 45 [Q1] → 42 (-3) [Q2]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 166%upside $10 | Buy Reiterated | 6 Sept 2024 |
Laidlaw & Co. Yale Jen 25% 1-year accuracy 1 / 4 met price target | 565%upside $25 | Buy Maintained | 13 Jun 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 166%upside $10 | Buy Reiterated | 13 Jun 2024 |
Financial journalist opinion
Based on 6 articles about AFMD published over the past 30 days